We are live on ! Find out more

Teleflex

TFX

Market cap $5.92B

139.77 USD

-1.62

1.15%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

139.77

0.00

0%

1 day

-1.15%

5 days

4.03%

1 month

11.78%

3 months

5.65%

6 months

12.8%

Year to date

14.19%

1 year

11.96%

5 years

-61.09%

10 years

-2.35%

About: Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.

Employees: 15,500

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.7%

Neutral 50%

Negative 14.3%

Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI). To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threateni.

Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold

Teleflex Announces Third Quarter 2026 Earnings Conference Call Information

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning.

Teleflex Announces Third Quarter 2026 Earnings Conference Call Information

Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding clinical evidence supporting the use of the F.

Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold

Zacks Investment Research

TFX or SONVY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?

TFX or SONVY: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Is It Prudent to Add Teleflex Stock to Your Portfolio Now?

TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.

Is It Prudent to Add Teleflex Stock to Your Portfolio Now?

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30.

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Zacks Investment Research

Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?

Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?

Zacks Investment Research

Here's Why Teleflex (TFX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Teleflex (TFX) is a Strong Value Stock

Zacks Investment Research

5 Low P/B Stocks That Offer Attractive Value and Growth

TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.

5 Low P/B Stocks That Offer Attractive Value and Growth

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

TFX vs. PEN: Which Stock Is the Better Value Option?

See News Rankings

Price charts implemented using Lightweight Charts™